Autonomix Preclinical Study Successfully Demonstrates That Nerve Ablation Can Slow Tumor Metastasis in Pancreatic Cancer
May 23 2024 - 9:15AM
Autonomix Medical, Inc. (NASDAQ: AMIX) (“Autonomix” or the
“Company”), a medical device company focused on advancing
innovative technologies to revolutionize how diseases involving the
nervous system are diagnosed and treated, today announced the
successful completion of an animal study evaluating the ability of
targeted nerve ablation to impact tumor metastases and growth.
For the preclinical mouse study, two groups of
mice received human pancreatic tumor cells (Mia PaCa2) into the
pancreatic head region. The experimental group received
peri-pancreatic neural ablation (ethanol infusion over the
pancreatic nerves) while the control group received no treatment.
Results of the experimental group demonstrated a statistically
significant reduction of the tumor mass growth and metastases.
Local invasion showed a 60% difference between the control and
experimental group while liver metastases showed a 40%
difference.
Lori Bisson, Chief Executive Officer of
Autonomix, commented, “The successful completion of this
preclinical animal study and highly encouraging results, support
the clinical literature suggesting that nerve fibers may be a
pathway for cancer cell metastasis tumor growth. The results
further support the concept that neural pathways are especially
impactful in the pathogenesis of pancreatic cancer. Even with a
small sample size in this preclinical study, the experimental group
demonstrated statistically significant metastasis reduction. While
our current proof of concept study in pancreatic cancer is strictly
focused on pain reduction from the ablation of target nerves near
the pancreas, additional studies will explore whether these
preclinical findings translate to the clinical application of our
technology. It is possible our ablation technology might slow human
pancreatic cancer growth and metastasis and may be investigated in
future clinical studies. Advancing clinical solutions for patients
fuels our continued efforts as we develop unique and proprietary
technologies to safely and reliably ablate nerves across multiple
indications, from pain to hypertension.”
The Company’s catheter-based sensing technology
is being developed to do two things: sense neural signals
associated with pain or disease and precisely target those nerves
for treatment. Autonomix believes this technology is a better
alternative to the current approaches commonly used today, where
doctors either rely on systemic drugs like opioids that lose
effectiveness and have unwanted side effects or treat suspected
areas blindly in hopes of hitting the right nerves, an approach
that is often inaccurate and can miss the target and even cause
collateral damage to surrounding parts of the body.
The Company is initially developing its
technology to address pancreatic cancer-related pain. Current
approaches, primarily relying on opioids or invasive ethanol
injections, can provide only limited relief and may lead to risky
side effects. For more information about the Company’s technology,
please visit autonomix.com.
About Autonomix Medical,
Inc.
Autonomix is a medical device company focused on
advancing innovative technologies to revolutionize how diseases
involving the nervous system are diagnosed and treated. The
Company’s first-in-class technology platform includes a
catheter-based microchip sensing array that has the ability to
detect and differentiate neural signals with approximately 3,000
times greater sensitivity than currently available technologies. We
believe this will enable, for the first time ever, transvascular
diagnosis and treatment of diseases involving the peripheral
nervous system virtually anywhere in the body.
We are initially developing technology for
pancreatic cancer pain, a condition that causes debilitating pain
and is without an effective solution. Our technology constitutes a
platform to address dozens of indications, including cardiology,
hypertension and chronic pain management, across a wide disease
spectrum.
For more information, visit autonomix.com and
connect with the Company on X, LinkedIn, Instagram and
Facebook.
Forward Looking Statements
Some of the statements in this release are
“forward-looking statements,” which involve risks and
uncertainties. Forward looking statements in this press release
include, without limitation, the potential of the technology to
treat hypertension and to complete its clinical study in pancreatic
cancer pain. Such forward-looking statements can be identified by
the use of words such as “should,” “might,” “may,” “intends,”
“anticipates,” “believes,” “estimates,” “projects,” “forecasts,”
“expects,” “plans,” and “proposes.”
Although Autonomix believes that the
expectations reflected in these forward-looking statements are
based on reasonable assumptions, there are a number of risks and
uncertainties that could cause actual results to differ materially
from such forward-looking statements. You are urged to carefully
review and consider any cautionary statements and other
disclosures, including the statements made under the heading “Risk
Factors” and elsewhere in the offering circular filed with the U.S.
Securities and Exchange Commission (“SEC”) on January 26, 2024.
Forward-looking statements speak only as of the date of the
document in which they are contained and Autonomix does not
undertake any duty to update any forward-looking statements except
as may be required by law.
Investor and Media Contact
JTC Team, LLCJenene
Thomas833-475-8247autonomix@jtcir.com
Autonomix Medical (NASDAQ:AMIX)
Historical Stock Chart
From May 2024 to Jun 2024
Autonomix Medical (NASDAQ:AMIX)
Historical Stock Chart
From Jun 2023 to Jun 2024